Trxade Health Inc
MEDS
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.77M
Close$
$-9.43
430.8% downside
Current Fair Value
430.8% downsideOvervalued by 430.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.77 Million |
|---|---|
| Enterprise Value | $37.93 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-71.5 |
| Beta | -1.52 |
| Outstanding Shares | 2,574,669 |
Return
| Return on Equity | 230324.93% |
|---|---|
| Return on Assets | -137130.30% |
| Return on Invested Capital | 706449.67% |
Valuation & Multiples
| P/E Ratio | -0.06 |
|---|---|
| PEG | -0.04 |
| Price to Sales | 0.02 |
| Price to Book Ratio | -0.36 |
| Enterprise Value to Revenue | 0.08 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.86 |
| Debt to Equity | -1.67 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Trxade Group Inc
9 employees
CEO: Shankar Hariharan Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops ...